回复：老大：如果可能，还是想听听你对它的revenue来源和负债

They have $1.5 b cash and $700 mil short term debt. So, they should have enough money to last to 2007. They currently have three drugs in the market place with annual revenue close to $500 mil, but the biggest potential is the Alzheimer drug, which is still in phase I and showing some promising results. If things go well with phase II, they'll ba able to raise enough money to carry the company through.
http://www.elan.com/Products/default.asp